FDG PET-CT for Lymphoma Radiotherapy Planning Version 1.3
NCT01999998 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2015-05-19
Summary
Chemotherapy followed by radiotherapy is used to treat early stage lymphomas with excellent cure rates. However, a significant proportion of these patients develop cancers and heart diseases years later as a result of the radiotherapy. Therefore, there is a move to reduce radiation exposure without compromising cure rates. Radiotherapy is planned using a CT scan taken following chemotherapy when many of the original sites of the lymphoma are no longer visible using a CT scan taken following chemotherapy when many of the original sites of the lymphoma are no longer visible.
In order to safely minimise the volume treated with radiotherapy it is necessary to accurately reconstruct the extent of the lymphoma prior to chemotherapy on this 'planning' CT scan. A PETCT prior to chemotherapy is the best way of demonstrating the original extent of the lymphoma, but is taken in a different position to the radiotherapy treatment position. This aim of this study is to explore whether a PETCT scan taken prior to chemotherapy in the radiotherapy treatment position, in conjunction with advanced software to combine this scan with the subsequent radiotherapy planning CT, can be used to more accurately identify the lymphoma target. The study aims to recruit up to 20 patients with early stage Hodgkin lymphoma or high grade nonHodgkin lymphoma. A routine staging PETCT will be followed at the same session by a PETCT in the radiotherapy treatment position appropriate radiotherapy immobilisation devices. Participation in the study will not affect treatment decisions or the radiotherapy planning process. The PETCT in the radiotherapy planning position will be made available to the treating clinicians. The process of planning radiotherapy will not be systematically altered by the study. The study is aimed at determining how to improve the radiotherapy planning process in the future, in the hope of a reducing in the long term side effects of treatment whilst retaining high cure rates.
Conditions
- Improve the Radiotherapy Planning Process
Interventions
- RADIATION
-
Radiotherapy
Sponsors & Collaborators
-
The Leeds Teaching Hospitals NHS Trust
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-08-31
- Primary Completion
- 2016-04-30
Countries
- United Kingdom
Study Locations
More Related Trials
-
18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
NCT05096234 ·Status: TERMINATED ·Phase: PHASE1
-
Remission Evaluation Before Intensified Treatment in Lymphoma: Impact of Positron Emission Tomography (PET) Using Fluorine-18-Floro-Deoxyglucose (FDG) in the Therapeutic Prescription. Medico-Economic Randomised Study
NCT00169598 ·Status: UNKNOWN ·Phase: NA
-
Assessment of Hematopoietic Recovery Following Chemotherapy for Non-Hodgkin's Lymphoma
NCT00775957 ·Status: TERMINATED
-
FDG-PET/CT Imaging as Early Predictor of DP
NCT02476734 ·Status: COMPLETED
-
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma
NCT03051581 ·Status: UNKNOWN ·Phase: NA
-
Early Diagnosis of Therapy-associated Cardiotoxicity Basing on PET/CT in Lymphoma
NCT05411250 ·Status: UNKNOWN
-
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma
NCT00110006 ·Status: WITHDRAWN ·Phase: NA
-
Clinical Usefulness and Prognostic Significance of Interim 18F-FDG PET/CT for the Treatment of Peripheral T Cell Lymphomas
NCT01470066 ·Status: UNKNOWN
-
PET-based Evaluation of Chemotherapy-induced Brain Damage in Lymphoma
NCT02601547 ·Status: COMPLETED ·Phase: NA
-
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
NCT00775268 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Creation of a Normal Database for FluoroDeoxyGlucose-Positron Emission Tomography (FDG-PET) Neurological Examinations
NCT02858167 ·Status: COMPLETED ·Phase: NA
-
Diffusion-weighted Magnetic Resonance Imaging in Post Therapy Patients With Lymphoma
NCT03969381 ·Status: UNKNOWN
-
Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma
NCT00915096 ·Status: COMPLETED
-
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma
NCT03051555 ·Status: UNKNOWN ·Phase: NA
-
18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma
NCT04317313 ·Status: COMPLETED
-
Early Evaluation of the Response of Large B Cell Non Hodgkin's Lymphoma to Chemotherapy by PET/CT
NCT00256490 ·Status: COMPLETED ·Phase: NA
-
Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET)
NCT01308905 ·Status: UNKNOWN ·Phase: NA
-
PET-CT in Lymphoma Among the Eldery
NCT07259941 ·Status: NOT_YET_RECRUITING
-
An International Study on the Use of PET/CT in Radiotherapy Planning in Low and Middle Income Countries
NCT02247713 ·Status: UNKNOWN
-
PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage IA or Stage IIA Hodgkin Lymphoma
NCT00943423 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers
NCT01421953 ·Status: COMPLETED ·Phase: NA
-
Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma
NCT03051568 ·Status: UNKNOWN ·Phase: NA
-
Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases
NCT05054998 ·Status: COMPLETED ·Phase: PHASE4
-
Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)
NCT01004718 ·Status: COMPLETED ·Phase: NA
-
18F-FDG Tomography and Labeled Leukocyte Scintigraphy
NCT05994768 ·Status: COMPLETED